Part of why doctors remain wary of cannabis medicine is the lack of randomized, double-blind, placebo controlled trials — the gold standard for medical research. Because of cannabis’ status as an illicit drug, research is often relegated to retrospective surveys, which are useful but more likely to be biased. But there are methods in between these two schemes, such as open-label trials.
“My name is Zoe Sigman, and I’m the Program Director at Project CBD, an educational nonprofit focused on cannabis science & medicine. Ten years ago, we introduced CBD to the medical cannabis community in California. It spread like wildfire and has become the hugely popular phenomenon that it is today.